A Phase 4 interventional study of Atorvastatin in Rheumatoid Arthritis, sponsored by University of California, Los Angeles. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-22.
Sponsored by University of California, Los Angeles · Phase 4, Interventional, and Treatment
This research evaluates the effects of a cholesterol-lowering medication, atorvastatin, on both arthritis activity and the ability of high-density lipoprotein cholesterol (HDL-C, sometimes referred to as "good cholesterol") to prevent changes in low-density lipoprotein cholesterol (LDL-C, sometimes referred to as "bad cholesterol"), which lead to atherosclerosis, or "hardening of the arteries." We hypothesize that atorvastatin may improve both joint inflammation and the anti-inflammatory properties of HDL cholesterol.
Heart attacks are the leading cause of death in patients with rheumatoid arthritis (RA). Cardiovascular events occur more frequently than would be expected in patients with RA and traditional heart risk factors do not explain this increased risk. Further research is needed to pursue ways of reducing heart disease mortality and improving outcome in patients with RA.
There is reason to believe that a class of cholesterol-lowering medications called statins, beneficial in cardiovascular disease prevention, may be able to reduce the irritation of the joints ("inflammation") associated with RA. Statins have been shown to reduce manifestations of inflammation in the blood of patients at increased risk for heart disease, and in the process reduce the risk of heart attack, stroke, and sudden death. Some similarities in the nature of both RA and heart disease may suggest potential benefits of statin therapy in both conditions.
In addition to inflammation, another factor which may contribute to coronary heart disease (CHD) risk in RA patients is dysfunctional high-density lipoprotein cholesterol (HDL-C, sometimes referred to as "good cholesterol"). Normally, HDL-C acts to counter a type of damage called "oxidation" within LDL-C which is a critical step in the development and progression of heart disease. Data from patients with RA and system lupus erythematosus (SLE) suggests that patients with active rheumatic diseases such as RA and SLE may have increased amounts of dysfunctional HDL-C, and therefore they may be at increased risk of heart disease. A blood test developed by Dr. Navab and colleagues at UCLA rapidly assesses this HDL-C function. This study will investigate both the level of HDL-C antioxidant function in patients with active RA as well as whether abnormal HDL function can be improved by statin use in this population. This research also evaluates the effects of atorvastatin on arthritis activity. We hypothesize that atorvastatin may improve both joint inflammation and the anti-inflammatory properties of HDL cholesterol.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 20 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Fulfill American College of Rheumatology (ACR) criteria for RA
At least 18 years of age
Have RA for at least one year with ongoing active disease (active disease defined as at least two of three: 1) ≥ six tender joints; 2) ≥ three swollen joints; 3) ≥ 45 minutes of morning stiffness)
Taking stable doses of disease modifying anti-rheumatic drug (DMARD) therapy for at least 3 months prior to study entry -
Exclusion Criteria:
Unable to give informed consent
Pregnant or lactating
Eligible for pharmacologic lipid-lowering therapy per National Cholesterol Treatment Program Adult Treatment Panel III guidelines
Using any lipid lowering medication
Known hepatic disease
Elevated liver transaminase levels within the past two months
Previous treatment in the last three months with hydroxychloroquine
-
Placebo
Drug: Atorvastatin
Atorvastatin
Drug: Atorvastatin
HDL anti-inflammatory properties at 0 and 12 weeks
Time frame: at 0 and 12 weeks
Highly sensitive C-reactive protein (hs-CRP) at 0 and 12 weeks
Time frame: at 0 and 12 weeks
Disease activity score using a 28 joint count (DAS28) at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Patient and physician global assessments on visual analogue pain scale (VAS; 0-100) at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Swollen and tender joint counts at 0,3,6,12,and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Patient pain assessment on VAS (0-100)at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Erythrocyte sedimentation rate(Westergren) at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Cholesterol levels at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
Health assessment questionnaire disability index (HAQ-DI) at 0,3,6,12, and 18 weeks
Time frame: at 0,3,6,12, and 18 weeks
No study locations are listed for this record.
This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles